Results 51 to 60 of about 1,394,911 (165)

Immune thrombocytopaenia in children and adolescents – current management and Polish perspective

Pediatria Polska
Immune thrombocytopaenia (ITP) is the most common cause of acquired thrombocytopaenia diagnosed in paediatric patients. It is described as an isolated thrombocytopaenia without other factors, which may cause a decrease in platelets.
Marta Andrzejewska, Ewelina Truszkowska, Katarzyna Derwich   +2 more
doaj   +1 more source

Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Pediatric Health, Medicine and Therapeutics, 2016
Michele P Lambert,1,2 1Division of Hematology, The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Pediatric data on the use of thrombopoietin ...
Lambert MP
doaj  

Biochemical pharmacology of the positive allosteric modulation of the GABAb receptor "in Vitro" and "in Vivo" [PDF]

, 2007
Allosteric modulators of G-protein coupled receptors (GPCRs) interact with binding sites on the receptor molecule that are topographically distinct from the classic orthosteric site.
Gjoni, Tina
core   +1 more source

Persistent Immune Thrombocytopenia as a Post‐Acute Sequelae of COVID‐19: A Case Report

Public Health Challenges, Volume 5, Issue 4, December 2026.
ABSTRACT Immune thrombocytopenia (ITP) is a recognized hematologic complication associated with coronavirus disease 2019 (COVID‐19), but its persistence years after acute infection remains uncommon. We present a case of a 52‐year‐old male who was diagnosed with COVID‐19 in June 2020. Following recovery from the acute illness, he had persistent fatigue,
Riazullah, Hakim Ullah Wazir, Aafeen Mujeeb, Hamid Ahmad, Hameed Ur Rehman, Inibehe Ime Okon   +5 more
wiley   +1 more source

Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: A case series [PDF]

, 2019
Thrombopoietin receptor agonists (TPO-RA) are currently approved to treat chronic immune thrombocytopenia (ITP) but there is increasing interest in considering these drugs earlier during the course of the disease. We present six patients with primary ITP
D'Amore F., Da Dalt G., Vianello F., Caputo I., Friziero A., Lombardi A. M.   +5 more
core   +1 more source

A marine sponge-derived lectin reveals hidden pathway for thrombopoietin receptor activation

, 2022
N-glycan-mediated activation of the thrombopoietin receptor (MPL) under pathological conditions has been implicated in myeloproliferative neoplasms induced by mutant calreticulin, which forms an endogenous receptor-agonist complex that traffics to the ...
Nakajima, Hiroya, Focia, Pamela J., Oshiro, Takumi, Sakai, Ryuichi, Tanaka, Yoshikazu, Kodera, Yoshio, Yokoyama, Takeshi, Masubuchi, Nami, Araki, Marito, Matsui, Takashi, Onodera, Kako, Komatsu, Norio, Ogawa, Tomohisa, Freymann, Douglas M., Watari, Hiromi, Hirayama, Makoto, Imai, Misa, Kageyama, Hiromu, Hori, Kanji   +18 more
core   +1 more source

Thrombocytopenia in Pregnancy: A 5‐Year Analysis of Characteristics and Practices From a Tertiary Academic Center

International Journal of Laboratory Hematology, Volume 48, Issue 6, Page 1320-1329, December 2026.
ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley   +1 more source

Romiplostim as a treatment for immune thrombocytopenia: a review

Journal of Blood Medicine, 2015
Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune ...
Chalmers S, Tarantino MD
doaj  

Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions

Cancer, Volume 132, Issue 22, 15 November 2026.
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato, Gloria Cocchetto, Simona Barbato, Michele Puppi, Simone Masci, Elena Zamagni   +5 more
wiley   +1 more source

Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature

Case Reports in Oncology, 2020
Immune thrombocytopenia (ITP) is a rare paraneoplastic syndrome of solid tumor malignancies. In previously described cases of renal cell carcinoma (RCC) associated with secondary ITP, treatment has consisted of nephrectomy, splenectomy, and ...
Dillon C. Cockrell, Raj S. Kasthuri, Ersan Altun, Tracy L. Rose, Matthew I. Milowsky   +4 more
doaj   +1 more source